Replimune Group, Inc. presented new analyses from its IGNYTE study of RP1 plus nivolumab in anti-PD1 failed melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2025. The presentations highlighted that RP1 plus nivolumab generated robust responses in both injected and non-injected lesions.
Data showed that deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only, and were generally well tolerated. A biosafety analysis poster indicated that RP1 is not airborne, retains sensitivity to acyclovir, and has a minimal likelihood of transmission.
These findings further support the broad applicability and safety profile of RP1, particularly its systemic anti-tumor effect and the feasibility of administering the therapy into deep-seated tumors. The biosafety data addresses important practical considerations for clinical use and handling of the oncolytic immunotherapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.